Lexeo Therapeutics, Inc. (LXEO)
(Delayed Data from NSDQ)
$11.12 USD
+2.02 (22.20%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $11.13 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.12 USD
+2.02 (22.20%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $11.13 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
by Ekta Bagri
Cassava Sciences, Inc. (SAVA) and Lexeo Therapeutics (LXEO) are in the spotlight following updates.
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
by Zacks Equity Research
Interim data from an early-stage study shows that treatment with Lexeo's (LXEO) experimental gene therapy reduced signs of heart complications in patients with Friedreich's ataxia.
What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock
by Zacks Equity Research
Lexeo Therapeutics, Inc. (LXEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Lexeo Therapeutics, Inc. (LXEO) points to a 57.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.